Background Colorectal cancer (CRC) is a heterogeneous disease with multiple underlying
causative genetic mutations. The B-type Raf proto-oncogene (BRAF) plays an important role …

Abstract Background and Aims: Numerous studies have identified BRAF V600E mutation as
a predictive factor of anti-EGFR antibodies in colorectal cancer (CRC). However, the …

Background Molecular markers in colon cancer are needed for a more accurate
classification and personalized treatment. We determined the effects on clinical outcome of …

BRAFV600E mutations are found in 10% of colorectal cancers (CRCs). The low frequency of
this mutation therefore makes it a challenging target for drug development, unless subsets of …

Background To prospectively evaluate the usefulness of the BRAF V600E mutation
detection in daily clinical practice in patients with metastatic Colorectal Cancer (mCRC) …

Purpose: Mutation of BRAF at the valine 600 residue occurs in approximately 10% of
colorectal cancers, a group with particularly poor prognosis. The response of BRAF mutant …

Although sequencing provides the gold standard for identifying colorectal carcinoma with
BRAF V600E mutation, immunohistochemistry (IHC) with the recently developed mouse …

Abstract Background Microsatellite stable (MSS) BRAF p. V600E mutation colorectal cancer
(BRAF-CRC) has a poor prognosis, whereas microsatellite instability (MSI) in BRAF-CRC is …

Simple Summary Colorectal cancer with a mutation in an oncogene BRAF has paid much
attention, as it comprises a population with dismal prognosis since two decades ago. A …

Background: In metastatic colorectal cancer (mCRC), BRAFV600E mutation has been
variously associated to specific clinico-pathological features. Methods: Two large …